摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,3-二-Boc-2-(羧基甲基)胍 | 158478-76-3

中文名称
1,3-二-Boc-2-(羧基甲基)胍
中文别名
N-(N,N′-二-BOC-脒基)甘氨酸
英文名称
(N,N'-bis(tert-butoxycarbonyl)carbamimidoyl)glycine
英文别名
1,3-Di-Boc-2-(carboxymethyl)guanidine;2-[bis[(2-methylpropan-2-yl)oxycarbonylamino]methylideneamino]acetic acid
1,3-二-Boc-2-(羧基甲基)胍化学式
CAS
158478-76-3
化学式
C13H23N3O6
mdl
——
分子量
317.342
InChiKey
ZJYJFQDYIMDGDG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    104-105 °C
  • 密度:
    1.20±0.1 g/cm3(Predicted)
  • 稳定性/保质期:
    常温常压下稳定,避免与强氧化剂接触。

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    22
  • 可旋转键数:
    8
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.69
  • 拓扑面积:
    126
  • 氢给体数:
    3
  • 氢受体数:
    7

安全信息

  • WGK Germany:
    3

SDS

SDS:27e44c904ee6d3ba04ce1f60554fb723
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    —— methyl (N,N'-bis(tert-butoxycarbonyl)carbamimidoyl)glycinate 1000312-21-9 C14H25N3O6 331.369
    —— ethyl 2-(N,N'-bis(tert-butyloxycarbonyl)guanidino)ethanoate 207725-91-5 C15H27N3O6 345.396
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    —— tert-butyl N-[N'-[2-(cyclohexylamino)-2-oxoethyl]-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]carbamate 1000312-29-7 C19H34N4O5 398.503

反应信息

点击查看最新优质反应信息

文献信息

  • Synthetic Receptors for the Differentiation of Phosphorylated Peptides with Nanomolar Affinities
    作者:Andreas Grauer、Alexander Riechers、Stefan Ritter、Burkhard König
    DOI:10.1002/chem.200800432
    日期:2008.10.10
    Artificial ditopic receptors for the differentiation of phosphorylated peptides varying in i+3 amino acid side chains were synthesized, and their binding affinities and selectivities were determined. The synthetic receptors show the highest binding affinities to phosphorylated peptides under physiological conditions (HEPES, pH 7.5, 154 mM NaCl) reported thus far for artificial systems. The tight and
    合成了用于区分 i+3 个氨基酸侧链不同的磷酸化肽的人工双位受体,并测定了它们的结合亲和力和选择性。迄今为止,合成受体在生理条件下(HEPES,pH 7.5,154 mM NaCl)对人工系统报道的磷酸化肽显示出最高的结合亲和力。通过受体分子中两个结合部分的高度协同性实现了紧密和选择性的结合。所有受体通过双(ZnII-环烯)复合物配位和识别羧酸盐或咪唑氨基酸侧链功能的第二个结合位点与磷酸化丝氨酸相互作用。
  • A Convenient Preparation of Monosubstituted<i>N</i>,<i>N</i>′-di(Boc)-Protected Guanidines
    作者:Brian Drake、Marcel Patek、Michal Lebl
    DOI:10.1055/s-1994-25527
    日期:——
    1-H-Pyrazole-1-[N,N′-bis(tert-butoxycarbonyl)] carboxamidine (1) reacts under mild conditions with a number of amines and amino acids to give the respective protected guanidines in moderate to high isolated yields.
    1-H 吡唑-1-[N,N′-双(叔丁氧羰基)]羧酰胺(1)在温和的条件下与多种胺和氨基酸反应,生成相应的受保护胍类化合物,分离产率从中等到高等不等。
  • DENDRITIC MOLECULAR INTRACELLULAR TRANSPORTERS AND METHODS OF MAKING AND USING SAME
    申请人:Harth Eva M.
    公开号:US20080221043A1
    公开(公告)日:2008-09-11
    In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to compounds comprising the structure: and at least one guanidinium residue, wherein m is zero or a positive integer. Also disclosed are methods of preparing the disclosed compounds. Also disclosed are methods of intracellular delivery comprising administering the disclosed compounds and compositions to a subject. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of one or more compounds or compositions of the invention and a pharmaceutically acceptable carrier. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    根据本发明的目的,本发明在一个方面涉及包含以下结构的化合物,以及至少一个鸟氨酸残基,其中m为零或正整数。还公开了制备所述化合物的方法。还公开了包括将所述化合物和组合物给予受试者的细胞内递送方法。还公开了包括本发明的一个或多个化合物或组合物的治疗有效量和药学可接受载体的制药组合物。本摘要旨在作为搜索特定领域的扫描工具,不限制本发明。
  • MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES
    申请人:Harth Eva M.
    公开号:US20090306335A1
    公开(公告)日:2009-12-10
    In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymer and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    本发明涉及聚合物、交联聚合物、功能化聚合物、纳米颗粒和功能化纳米颗粒以及其制备和使用方法。其中,本发明涉及可降解聚合物和可降解纳米颗粒。本发明还涉及制备可降解纳米颗粒的方法,更具体地说,涉及在制备可降解纳米颗粒过程中控制颗粒大小的方法。在一方面,这些可降解纳米颗粒可用于复合、传递和释放药物活性载荷等方面。本摘要旨在作为搜索特定技术领域的扫描工具,不限制本发明。
  • Multifunctional Degradable Nanoparticles with Control over Size and Functionalities
    申请人:Harth Eva M.
    公开号:US20110257343A1
    公开(公告)日:2011-10-20
    In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymer and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    一方面,本发明涉及聚合物、交联聚合物、功能化聚合物、纳米颗粒和功能化纳米颗粒的制备和使用方法。另一方面,本发明涉及可降解聚合物和可降解纳米颗粒。另一方面,本发明涉及制备可降解纳米颗粒的方法,更具体地说,涉及在制备可降解纳米颗粒过程中控制颗粒大小的方法。另一方面,可降解纳米颗粒可用于复合、传递和释放药物活性载荷等用途。本摘要旨在作为搜索特定领域的扫描工具,不限制本发明。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物